UK Peptide Law & the MHRA Explained
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines in the UK. This page explains, in plain English, how its remit applies to peptide research compounds.
Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.
The medicinal product concept
Under the Human Medicines Regulations 2012, a substance is a “medicinal product” if it is either:
- Presented as having properties for treating or preventing disease (presentational limb), or
- Used by, or administered to, a human with a view to restoring, correcting or modifying physiological function — by exerting pharmacological, immunological or metabolic action — or to making a medical diagnosis (functional limb).
The test depends on how a compound is presented and used, not what its label says. A compound sold as “research use only” can still meet the definition of a medicinal product if the surrounding marketing and supply context presents it as a treatment.
The MHRA’s role
The MHRA is responsible for assessing medicinal products for safety, quality, and efficacy; granting marketing authorisations; monitoring adverse events through the Yellow Card scheme; and enforcing the Human Medicines Regulations. It also regulates clinical trials of investigational medicinal products under the Medicines for Human Use (Clinical Trials) Regulations 2004 and, post-Brexit, the supplemented UK regime that operates alongside it.
The MHRA’s detailed framing of the medicinal-product test sits in its Guidance Note 8: A Guide to What is a Medicinal Product — readers wanting to go beyond this summary should consult that document directly.
Why unapproved peptides sit in a difficult position
Most peptides on this site are not approved medicines in the UK. They have no marketing authorisation, no clinician information, and no sanctioned indication. They can be sold for laboratory research, but supplying them to a member of the public for human use — or marketing them with medicinal claims — can engage the medicines regulations.
Why we avoid promotional framing
Because the presentational limb of the definition is broad, the framing of content on a peptide page can itself be regulatory-relevant. We therefore avoid “best for X” superlatives, recommended-dose figures intended for human use, and before/after styles that turn educational content into promotion. See: POM advertising rules.
Related framework
Peptides may also engage:
- Misuse of Drugs Act 1971 for specific controlled compounds.
- Psychoactive Substances Act 2016 in narrow cases.
- Veterinary Medicines Regulations 2013 for animal-administration claims.
- UK Anti-Doping rules / WADA Code for athletes (see anti-doping).
- ASA / CAP Code for advertising — particularly relevant for cosmetic-adjacent peptides.
Not legal advice
This is an educational summary. Specific questions about a particular peptide or supply context should be put to a qualified solicitor or to the MHRA directly.